Cartesian Therapeutics outlines 2025 priorities; Phase 3 MG trial to start in 1H25

Cartesian Therapeutics, Inc.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; primary endpoint is MG-ADL improvement ≥3 points at Month 4 vs placebo.
Update Phase 2b MG data: average MG-ADL reduction of 5.5 at Month 4 (n=12); deepening responses over time; no need for preconditioning chemo.
Phase 2 SLE trial of Descartes-08 enrolling; data readout expected in 2H25. SLE affects ~1.5M people in the US.
Descartes-15 Phase 1 dose escalation ongoing in multiple myeloma; after Phase 1, will assess in autoimmune indications.
Cash runway expected to support operations, including completion of Phase 3 MG trial, into mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.